HER2/NEU AND CD3 EXPRESSION IN BREAST CANCER ASSOCIATED WITH DIABETES
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.47Keywords:
Breast cancer, diabetes mellitus, CD3, HER2/neu, NST carcinomasAbstract
Breast cancer is one of the most common neoplasms globally, being responsible for a high mortality rate, especially in the presence of comorbidities such as diabetes mellitus (DM). In this context, molecular markers such as CD3 and HER2/neu play an essential role. CD3 is a crucial protein for the function and activation of T cells, playing a central role in antitumor immunity. Similarly, the HER2/neu receptor, a member of the epidermal growth factor receptor (EGFR) family, is directly involved in processes of cellular proliferation, angiogenesis and tumor aggressiveness in breast cancer. The aim of this study was to evaluate the expression of CD3 and HER2/neu markers in NST (non-special type) breast carcinomas in patients with and without type 2 DM. The analysis focuses on correlating the expression levels of these markers with the presence of diabetes mellitus and the clinicopathological characteristics of the tumors.
References
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, și A. Jemal, „Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”, CA: A Cancer Journal for Clinicians, vol. 68, nr. 6, pp. 394– 424, 2018, doi: https://doi.org/10.3322/caac.21492.
„PCN-33-DZ.pdf”. Data accesării: 31 iulie 2022. [Online]. Disponibil la: https://msmps.gov.md/wp-content/uploads/2021/02/PCN-33-DZ.pdf
P. Saeedi et al., „Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, Diabetes Research and Clinical Practice, vol. 157, nov. 2019, doi: 10.1016/j.diabres.2019.107843.
M. J. L. Verhulst, B. G. Loos, V. E. A. Gerdes, și W. J. Teeuw, „Evaluating All Potential Oral Complications of Diabetes Mellitus”, Front Endocrinol (Lausanne), vol. 10, p. 56, feb. 2019, doi: 10.3389/fendo.2019.00056.
R. Chetty și K. Gatter, „CD3: Structure, function, and role of immunostaining in clinical practice”, The Journal of Pathology, vol. 173, nr. 4, pp. 303–307,1994, doi: 10.1002/path.1711730404.
R. A. Mariuzza, P. Agnihotri, și J. Orban, „The structural basis of T-cell receptor (TCR) activation: An enduring enigma”, Journal of Biological Chemistry, vol. 295, nr. 4, pp. 914–925, ian. 2020, doi: 10.1016/ S0021-9258(17)49904-2.
A. Fischer, G. de Saint Basile, și F. Le Deist, „CD3 deficiencies”, Current Opinion in Allergy and Clinical Immunology, vol. 5, nr. 6, pp. 491–495, dec. 2005, doi: 10.1097/01.all.0000191886.12645.79.
H. Xu et al., „Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood”, Biomaterials, vol. 32, nr. 36, pp. 9758–9765, dec. 2011, doi: 10.1016/j.biomaterials.2011.08.076.
J. Baumann, J. Wong, Y. Sun, și D. S. Conklin,„Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells”, BMC Cancer, vol. 16, nr. 1, p. 551, iul. 2016, doi: 10.1186/s12885-016-2611-8.
L. Blasquez, H. Bouzinba-Segard, S. Bourdoulous, și C. Faure, „Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers”, Molecular Oncology, vol. 17, nr. 10, pp. 1981–1999, 2023, doi: 10.1002/1878-0261.13419.
M. D. Onsum et al., „Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients”, The American Journal of Pathology, vol. 183, nr. 5, pp. 1446–1460, nov. 2013, doi: 10.1016/j.ajpath.2013.07.015.
U. Wuellner et al., „Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity”, Antibodies, vol. 4, nr. 4, Art. nr. 4, dec. 2015, doi: 10.3390/antib4040426.
J. Xing et al., „BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells”, Translational Oncology, vol. 10, nr. 5, pp. 780–785, oct. 2017, doi: 10.1016/j.tranon.2017.07.003.
A. Lopez-Albaitero et al., „Overcoming resistance to HER2-targeted therapy with a novel HER2/ CD3 bispecific antibody”, OncoImmunology, vol. 6, nr. 3, p. e1267891, mar. 2017, doi: 10.1080/2162402X.2016.1267891.
D. Slaga et al., „Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3”, Science Translational Medicine, vol. 10, nr. 463, p. eaat5775, oct. 2018, doi: 10.1126/ scitranslmed.aat5775.
J. Li et al., „IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody”, Clinical Cancer Research, vol. 24, nr. 24,pp. 6447–6458, dec. 2018, doi: 10.1158/1078-0432. CCR-18-1139.
Y. Zhou et al., „Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer”, Molecular Medicine Reports, vol. 12, nr. 1,pp. 147–154, iul. 2015, doi: 10.3892/mmr.2015.3441.
M. Okabe et al., „Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer”, Cancer Science, vol. 108, nr. 1, pp. 81–90, 2017, doi: 10.1111/cas.13114.
Y. Hou et al., „PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2- positive invasive breast cancer”, The Breast Journal, vol. 24, nr. 6, pp. 911–919, 2018, doi: 10.1111/tbj.13112.
R. Salgado et al., „The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014”, Ann Oncol, vol. 26, nr. 2, pp. 259–271, feb. 2015, doi: 10.1093/annonc/mdu450.
S. S. Chung, N. Giehl, Y. Wu, și J. V. Vadgama,„STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits”, International Journal of Oncology, vol. 44, nr. 2, pp. 403–411, feb. 2014, doi: 10.3892/ijo.2013.2195.
X. Wang, N. Zhang, S. LI, D. Yin, și Y. Liu, „Prognostic implications of stromal tumor-infiltrating lymphocytes and programmed death ligand 1 expression in HER2- positive invasive breast cancer”, 4 iunie 2020, Research Square. doi: 10.21203/rs.3.rs-29327/v2.
L.-C. Tsao et al., „CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody- dependent cellular phagocytosis”, JCI Insight, vol. 4, nr. 24, dec. 2019, doi: 10.1172/jci.insight.131882.
M. Z. Ladjemi, W. Jacot, T. Chardès, A. Pèlegrin, și I. Navarro-Teulon, „Anti-HER2 vaccines: new prospects for breast cancer therapy”, Cancer Immunol Immunother, vol. 59, nr. 9, pp. 1295–1312, sep. 2010, doi: 10.1007/s00262-010-0869-2.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
